# KG_Explain: å¯è§£é‡ŠçŸ¥è¯†å›¾è°±è¯ç‰©é‡å®šä½ç³»ç»Ÿ

> æ„å»º **Drug â†’ Target â†’ Pathway â†’ Disease** å¤šè·³å¯è§£é‡Šè·¯å¾„ï¼Œè¾“å‡º**æœºåˆ¶çº§è¯æ®åŒ…**ã€‚
> æ”¯æŒä¸¤ç§è¯ç‰©æ¥æºæ¨¡å¼: **CT.gov å¤±è´¥è¯•éªŒ** (ç»å…¸) å’Œ **åŸºå› ç­¾ååæŸ¥** (è·¨ç–¾ç—… repurposing)ã€‚

---

## æ•´ä½“å®šä½

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  dsmeta_signature    â”‚     â”‚     SigReverse        â”‚     â”‚   KG_Explain         â”‚
â”‚                      â”‚     â”‚                       â”‚     â”‚   (æœ¬é¡¹ç›®)           â”‚
â”‚  GEO åŸå§‹æ•°æ®        â”‚     â”‚  disease_signature    â”‚     â”‚                      â”‚
â”‚  â†’ å·®å¼‚è¡¨è¾¾          â”‚     â”‚  â†’ LINCS L1000 æŸ¥è¯¢   â”‚     â”‚  è¯ç‰©æ¥æº (äºŒé€‰ä¸€):  â”‚
â”‚  â†’ Meta åˆ†æ         â”‚     â”‚  â†’ CMap åå‘è¯„åˆ†      â”‚     â”‚  A) CT.gov å¤±è´¥è¯•éªŒ  â”‚
â”‚  â†’ ç–¾ç—…ç­¾å JSON  â”€â”€â”€â”¼â”€â”€â”€â”€â†’â”‚  â†’ è¯ç‰©æ’åº           â”‚     â”‚  B) åŸºå› ç­¾ååæŸ¥ â”€â”€â”€â”€â”¤
â”‚                      â”‚  â”‚  â”‚                       â”‚     â”‚                      â”‚
â”‚                      â”‚  â”‚  â”‚  (å¯é€‰) èåˆ KG åˆ†æ•° â†â”¼â”€â”€â”€â”€â”€â”¤  â†’ Drug-Target       â”‚
â”‚                      â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â”‚  â†’ Target-Pathway    â”‚
â”‚                      â”‚  â”‚                                â”‚  â†’ Pathway-Disease   â”‚
â”‚                      â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€ disease_signature â”€â”€â”€â†’â”‚  â†’ å®‰å…¨ + è¡¨å‹æ‰“åˆ†   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    meta.json (Signature æ¨¡å¼)     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
       é€ ç­¾å                     æ‰¾åè½¬è¯ç‰©                      æ‰¾æœºåˆ¶è¯æ®
     (è‡ªä¸‹è€Œä¸Š)                 (è¡¨è¾¾è°±åŒ¹é…)                    (è‡ªä¸Šè€Œä¸‹)

                         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                         â”‚  LLM+RAG è¯æ®å·¥ç¨‹     â”‚
                         â”‚                      â”‚
                         â”‚  PubMed æ–‡çŒ®æŒ–æ˜      â”‚
                         â”‚  â†’ LLM è¯æ®æå–      â”‚
                         â”‚  â†’ å‡è®¾å¡ + è¯„åˆ†      â”‚
                         â”‚  â† bridge_repurpose_   â”‚
                         â”‚    rag.csv (æ¥è‡ªæœ¬é¡¹ç›®)â”‚
                         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               æ–‡çŒ®è¯æ®è¡¥å……
```

å››ä¸ªé¡¹ç›®**äº’è¡¥**ï¼šdsmeta é€ ç­¾å â†’ SigReverse æ‰¾è¯ â†’ KG_Explain è§£é‡Šæœºåˆ¶ â†’ LLM+RAG è¡¥å……æ–‡çŒ®è¯æ®ã€‚

---

## ä¸¤ç§è¯ç‰©æ¥æºæ¨¡å¼

### æ¨¡å¼ A: CT.gov å¤±è´¥è¯•éªŒ (ç»å…¸æ¨¡å¼, `--drug-source ctgov`)

ä» ClinicalTrials.gov æœç´¢ç›®æ ‡ç–¾ç—…çš„å¤±è´¥/ç»ˆæ­¢/æ’¤å›è¯•éªŒ â†’ æå–è¯ç‰© â†’ æŸ¥é¶ç‚¹ â†’ æ‰¾é€šè·¯ â†’ å…³è”ç–¾ç—…ã€‚

**é€‚åˆ**: å·²çŸ¥ç–¾ç—…é¢†åŸŸå†…çš„è¯ç‰©é‡å®šä½ (å¦‚"å¿ƒè¡€ç®¡è¯ç‰©æ²»å…¶ä»–å¿ƒè¡€ç®¡ç—…")ã€‚

**å±€é™**: è¯ç‰©æ¥æºè¢«é”å®šåœ¨ç›®æ ‡ç–¾ç—…é¢†åŸŸï¼Œéš¾ä»¥å‘ç°çœŸæ­£çš„è·¨ç–¾ç—… repurposingã€‚

### æ¨¡å¼ B: åŸºå› ç­¾ååæŸ¥ (Signature æ¨¡å¼, `--drug-source signature`) ğŸ†•

ä» dsmeta è¾“å‡ºçš„ç–¾ç—…åŸºå› ç­¾å (up/down-regulated genes) å‡ºå‘ â†’ åæŸ¥ ChEMBL ä¸­ä½œç”¨äºè¿™äº›åŸºå› çš„è¯ç‰© (Phase II+) â†’ è¯ç‰©æ¥è‡ªå¤šä¸ªä¸åŒç–¾ç—…é¢†åŸŸ â†’ çœŸæ­£çš„è·¨ç–¾ç—… drug repurposingã€‚

**é€‚åˆ**: å‘ç°æ¥è‡ªå…¶ä»–ç–¾ç—…é¢†åŸŸçš„è¯ç‰©ï¼Œé€šè¿‡å…±äº«é¶ç‚¹/é€šè·¯ä½œç”¨äºç›®æ ‡ç–¾ç—…ã€‚

**ä¼˜åŠ¿**:
- è¯ç‰©æ¥è‡ªå¤šä¸ªæ²»ç–—é¢†åŸŸ (è‡ªå…ã€è‚¿ç˜¤ã€è¡€æ¶²ã€çœ¼ç§‘ç­‰)
- è‡ªåŠ¨æ ‡è®°å·²çŸ¥é€‚åº”ç—‡ (`is_known_indication`)
- ä»æœºåˆ¶å±‚é¢è§£é‡Š"ä¸ºä»€ä¹ˆè¿™ä¸ªè¯å¯èƒ½å¯¹ç›®æ ‡ç–¾ç—…æœ‰æ•ˆ"

---

## æ•°æ®æµ

### æ¨¡å¼ A: CT.gov å¤±è´¥è¯•éªŒæ¨¡å¼ (10 æ­¥ + æ’åº)

```
configs/
  â”œâ”€â”€ base.yaml                      åŸºç¡€é…ç½® (API ç«¯ç‚¹ã€æ–‡ä»¶å)
  â”œâ”€â”€ diseases/atherosclerosis.yaml  ç–¾ç—…é…ç½® (CT.gov æ¡ä»¶ã€ICD-10)
  â””â”€â”€ versions/v5.yaml              V5 å‚æ•° (å®‰å…¨æƒé‡ã€è¡¨å‹åŠ æˆ)

    â–¼ â”€â”€â”€ Step 1: fetch ctgov â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  ä» ClinicalTrials.gov æœç´¢å¤±è´¥/ç»ˆæ­¢/æ’¤å›çš„ä¸´åºŠè¯•éªŒ
    â”‚  â€¢ çŠ¶æ€: TERMINATED, WITHDRAWN, SUSPENDED
    â”‚  â€¢ æå–: è¯ç‰©åç§° + è¯•éªŒçŠ¶æ€ + åœæ­¢åŸå› 
    â”‚  â€¢ å¹²é¢„ç±»å‹è¿‡æ»¤: DRUG + BIOLOGICAL (æ’é™¤ DEVICE ç­‰)
    â–¼
  data/failed_trials_drug_rows.csv

    â–¼ â”€â”€â”€ Step 2: fetch rxnorm â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  RxNorm è¯ç‰©åç§°æ ‡å‡†åŒ– (RxNav REST API)
    â–¼
  data/drug_rxnorm_map.csv

    â–¼ â”€â”€â”€ Step 3: build canonical â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  æ„å»ºæ ‡å‡†åŒ–è¯ç‰©å (åˆå¹¶åˆ«å)
    â–¼
  data/drug_canonical.csv

    â–¼ â”€â”€â”€ Step 4: fetch chembl â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  ChEMBL è¯ç‰© ID æ˜ å°„
    â”‚  â€¢ å…ˆç²¾ç¡®åŒ¹é… â†’ åæ¨¡ç³Šæœç´¢ â†’ ç›ç±»â†’æ¯ä½“åˆ†å­
    â–¼
  data/drug_chembl_map.csv

    â–¼ â”€â”€â”€ Step 5: fetch targets â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  ChEMBL è¯ç‰©-é¶ç‚¹å…³ç³» (Mechanism of Action)
    â–¼
  data/edge_drug_target.csv

    â–¼ â”€â”€â”€ Step 6-10 + Ranking: (å…±äº«æ­¥éª¤, è§ä¸‹æ–¹) â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
```

### æ¨¡å¼ B: åŸºå› ç­¾ååæŸ¥æ¨¡å¼ (Signature) ğŸ†•

```
è¾“å…¥: dsmeta_signature_pipeline/outputs/signature/disease_signature_meta.json
       (300 up-regulated + 300 down-regulated genes, å« weight)

configs/
  â”œâ”€â”€ base.yaml
  â”œâ”€â”€ diseases/atherosclerosis.yaml
  â””â”€â”€ versions/v5_signature.yaml     Signature é…ç½® (max_phaseâ‰¥2)

    â–¼ â”€â”€â”€ Step 1: åŸºå› ç­¾å â†’ è¯ç‰©åæŸ¥ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚
    â”‚  disease_signature_meta.json
    â”‚  â†’ å– top 100 åŸºå›  (æŒ‰ weight æ’åº, up + down)
    â”‚  â†’ Gene Symbol â†’ UniProt Accession (MyGene.info)
    â”‚  â†’ UniProt â†’ ChEMBL Target ID
    â”‚  â†’ ChEMBL Target â†’ Drug Molecules (mechanism.json)
    â”‚  â†’ ç­›é€‰: max_phase â‰¥ 2 (Phase II åŠä»¥ä¸Š)
    â”‚
    â”‚  åŒæ—¶è¾“å‡ºå…¼å®¹ Step 2-5 çš„å ä½æ–‡ä»¶:
    â”‚  â€¢ drug_chembl_map.csv      (è¯ç‰©æ˜ å°„)
    â”‚  â€¢ edge_drug_target.csv     (è¯ç‰©-é¶ç‚¹å…³ç³»)
    â”‚  â€¢ drug_canonical.csv       (æ ‡å‡†å)
    â”‚  â€¢ drug_rxnorm_map.csv      (å ä½, ç©º)
    â”‚  â€¢ failed_trials_drug_rows.csv  (å ä½, ç©º)
    â”‚  â€¢ failed_drugs_summary.csv     (æ ‡è®° source=signature)
    â–¼
  data/drug_from_signature.csv       å®Œæ•´åæŸ¥ç»“æœ (è¯ç‰©+é¶ç‚¹+åŸºå› +æ–¹å‘+æƒé‡)
  data/drug_chembl_map.csv           è¯ç‰©æ˜ å°„ (å…¼å®¹åç»­æ­¥éª¤)
  data/edge_drug_target.csv          è¯ç‰©-é¶ç‚¹è¾¹ (å…¼å®¹åç»­æ­¥éª¤)

    â­ Step 2-5: è·³è¿‡ (Signature æ¨¡å¼å·²ç›´æ¥ç”Ÿæˆ)

    â–¼ â”€â”€â”€ å…±äº«æ­¥éª¤ (ä¸¤ç§æ¨¡å¼ç›¸åŒ) â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
```

### å…±äº«æ­¥éª¤ (Step 6-10 + Ranking)

```
    â–¼ â”€â”€â”€ Step 6: Target Xref + Ensembl â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  ChEMBL Target â†’ UniProt â†’ Ensembl Gene ID
    â–¼
  data/target_xref.csv
  data/target_chembl_to_ensembl_all.csv

    â–¼ â”€â”€â”€ Step 7: Target â†’ Pathway (Reactome) â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  æ¯ä¸ªè›‹ç™½è´¨ â†’ æ‰€å‚ä¸çš„ç”Ÿç‰©é€šè·¯ (å¹¶è¡Œ API)
    â–¼
  data/edge_target_pathway_all.csv

    â–¼ â”€â”€â”€ Step 8: Gene â†’ Disease (OpenTargets) â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  GraphQL API v4, è¿‡æ»¤éç–¾ç—… ID (GO_/MP_)
    â–¼
  data/edge_target_disease_ot.csv

    â–¼ â”€â”€â”€ Step 9: Build Edges â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚  gene_pathway + pathway_disease + trial_ae (èšåˆæ¸…æ´—)
    â–¼
  data/edge_gene_pathway.csv
  data/edge_pathway_disease.csv
  data/edge_trial_ae.csv

    â–¼ â”€â”€â”€ Step 10: FAERS + Phenotypes + Known Indications â”€â”€â”€â”€â”€
    â”‚  â€¢ FAERS å®‰å…¨ä¿¡å· (PRR, ä¸¥é‡ AE)
    â”‚  â€¢ Disease â†’ Phenotype (OpenTargets, min_score â‰¥ 0.3)
    â”‚  â€¢ ChEMBL drug_indication â†’ å·²çŸ¥é€‚åº”ç—‡ (Signature æ¨¡å¼)
    â–¼
  data/edge_drug_ae_faers.csv
  data/edge_disease_phenotype.csv
  data/drug_known_indications.csv    (Signature æ¨¡å¼æ–°å¢)

    â–¼ â”€â”€â”€ Ranking: V5 æ’åº â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
    â”‚
    â”‚  æ ¸å¿ƒå…¬å¼:
    â”‚    final = mechanism Ã— exp(-w1Ã—safety - w2Ã—trial_penalty)
    â”‚                      Ã— (1 + w3Ã—log1p(min(n_phenotype,10)))
    â”‚
    â”‚  Signature æ¨¡å¼é¢å¤–è¾“å‡º:
    â”‚    â€¢ is_known_indication: æ˜¯å¦ä¸ºå·²çŸ¥é€‚åº”ç—‡ (æ ‡è®°, ä¸æ’é™¤)
    â”‚    â€¢ original_indications: è¯¥è¯å·²æ‰¹å‡†çš„é€‚åº”ç—‡åˆ—è¡¨
    â”‚    â€¢ signature_genes: è§¦å‘åæŸ¥çš„ç­¾ååŸºå› 
    â”‚    â€¢ n_signature_targets: è¯¥è¯å‘½ä¸­çš„ç­¾åé¶ç‚¹æ•°
    â–¼
  output/
  â”œâ”€â”€ drug_disease_rank_v5.csv      æœ€ç»ˆæ’åº (å« is_known_indication + CI åˆ—)
  â”‚                                 ci_lower, ci_upper, ci_width, confidence_tier, n_evidence_paths
  â”œâ”€â”€ evidence_paths_v5.jsonl       æ‰€æœ‰è·¯å¾„ (JSONL)
  â”œâ”€â”€ evidence_pack_v5/             æ¯å¯¹è¯æ®åŒ… (JSON)
  â”œâ”€â”€ bridge_repurpose_cross.csv   Direction A: è·¨ç–¾ç—…è¿ç§» bridge
  â”œâ”€â”€ bridge_origin_reassess.csv   Direction B: åŸç–¾ç—…é‡è¯„ä¼° bridge (generate_disease_bridge.py)
  â””â”€â”€ pipeline_manifest.json        è¿è¡Œå…ƒæ•°æ® (è®¡æ—¶ã€ç¼“å­˜ã€è¯ç‰©æ¥æº)
```

---

## ä½ éœ€è¦æä¾›ä»€ä¹ˆ

### CT.gov æ¨¡å¼
1. **ç–¾ç—…æ–¹å‘** â€” CT.gov æœç´¢æ¡ä»¶ (å¦‚ "atherosclerosis")
2. **æ’åºç‰ˆæœ¬** â€” æ¨è V5

### Signature æ¨¡å¼
1. **ç–¾ç—…æ–¹å‘** â€” ç–¾ç—…åç§° (ç”¨äº OpenTargets æŸ¥è¯¢)
2. **ç­¾åæ–‡ä»¶** â€” dsmeta_signature_pipeline è¾“å‡ºçš„ `disease_signature_meta.json`
3. **æ’åºç‰ˆæœ¬** â€” æ¨è V5

---

## ä½ èƒ½å¾—åˆ°ä»€ä¹ˆ

| æ–‡ä»¶ | è¯´æ˜ |
|------|------|
| `output/drug_disease_rank_v5.csv` | è¯ç‰©-ç–¾ç—…æ’åº (final_score, mechanism, safety, is_known_indication) |
| `output/evidence_paths_v5.jsonl` | æ‰€æœ‰ DTPD è·¯å¾„ (æ¯è¡Œä¸€ä¸ª JSON) |
| `output/evidence_pack_v5/*.json` | â˜… æ¯å¯¹è¯-ç–¾ç—…çš„å®Œæ•´è¯æ®åŒ… |
| `output/bridge_repurpose_cross.csv` | Direction A: è·¨ç–¾ç—…è¿ç§» bridge (æ¯è¯æœ€é«˜åˆ†ç–¾ç—…) |
| `output/bridge_origin_reassess.csv` | Direction B: åŸç–¾ç—…é‡è¯„ä¼° bridge (ç›®æ ‡ç–¾ç—… + æ–‡çŒ®æ³¨å…¥) |
| `output/pipeline_manifest.json` | è¿è¡Œå…ƒæ•°æ® (è®¡æ—¶ã€ç¼“å­˜å‘½ä¸­ç‡ã€é…ç½®æ‘˜è¦) |
| `data/drug_from_signature.csv` | (Signature) åæŸ¥ç»“æœ (è¯ç‰©+é¶ç‚¹+åŸºå› +æƒé‡) |
| `data/drug_known_indications.csv` | (Signature) å„è¯ç‰©å·²çŸ¥é€‚åº”ç—‡åˆ—è¡¨ |
| `data/edge_*.csv` | æ‰€æœ‰ä¸­é—´è¾¹æ•°æ® (å¯å¤ç”¨) |

---

## å®‰è£…

```bash
pip install -r requirements.txt
mkdir -p data output cache
```

ä¾èµ–: Python 3.12 + pandas + numpy + requests + tenacity + networkx + pyyaml + tqdm

---

## è¿è¡Œ

### CT.gov æ¨¡å¼ (ç»å…¸)

```bash
# å®Œæ•´ç®¡é“
python -m kg_explain pipeline --disease atherosclerosis --version v5

# ä»…æ’åº (å‡è®¾æ•°æ®å·²å­˜åœ¨)
python -m kg_explain rank --version v5
```

### Signature æ¨¡å¼ (è·¨ç–¾ç—… repurposing) ğŸ†•

```bash
# å®Œæ•´ç®¡é“ â€” ä»åŸºå› ç­¾ååæŸ¥è¯ç‰©
python -m kg_explain pipeline \
  --disease atherosclerosis \
  --version v5 \
  --drug-source signature \
  --signature-path ../dsmeta_signature_pipeline/outputs/signature/disease_signature_meta.json
```

### åˆ†æ­¥è·å–æ•°æ®

```bash
# CT.gov æ¨¡å¼
python -m kg_explain fetch ctgov --condition atherosclerosis
python -m kg_explain fetch rxnorm
python -m kg_explain fetch chembl
python -m kg_explain fetch targets
python -m kg_explain fetch pathways
python -m kg_explain fetch diseases
python -m kg_explain fetch faers
python -m kg_explain fetch phenotypes

# Signature æ¨¡å¼ (å•ç‹¬åæŸ¥)
python -m kg_explain fetch signature \
  --signature-path ../dsmeta_signature_pipeline/outputs/signature/disease_signature_meta.json
```

### æ„å»ºä¸­é—´è¾¹

```bash
python -m kg_explain build gene-pathway
python -m kg_explain build pathway-disease
python -m kg_explain build trial-ae
```

### è¯„ä¼° (éœ€è¦é‡‘æ ‡å‡†)

```bash
python -m kg_explain benchmark --version v5 --gold gold_standard.csv --ks 5,10,20
```

---

## å¯¹æ¥å…¶ä»–é¡¹ç›®

### â†’ SigReverse (èåˆæœºåˆ¶åˆ†)

```bash
# KG_Explain äº§å‡ºæ’åº
python -m kg_explain pipeline --disease atherosclerosis --version v5

# SigReverse èåˆ KG åˆ†æ•°
cd ../sigreverse
python scripts/run_fusion_with_kg.py \
    --sigreverse-csv data/output/drug_reversal_rank.csv \
    --kg-csv ../kg_explain/output/drug_disease_rank_v5.csv \
    --faers-csv ../kg_explain/data/edge_drug_ae_faers.csv \
    --disease atherosclerosis \
    --out data/output/fused_rank.csv
```

### â†’ LLM+RAG è¯æ®å·¥ç¨‹ (è¡¥å……æ–‡çŒ®è¯æ®)

ä¸¤ä¸ªæ–¹å‘çš„ bridge æ–‡ä»¶ï¼Œåˆ†åˆ«å–‚ç»™ LLM+RAG:

```bash
# Direction A: è·¨ç–¾ç—…è¿ç§» (bridge_repurpose_cross.csv)
cd ../LLM+RAGè¯æ®å·¥ç¨‹
python scripts/step6_evidence_extraction.py \
    --rank_in ../kg_explain/output/bridge_repurpose_cross.csv \
    --out output/step6_repurpose_cross \
    --target_disease atherosclerosis --topn 50

# Direction B: åŸç–¾ç—…é‡è¯„ä¼° (bridge_origin_reassess.csv)
python scripts/step6_evidence_extraction.py \
    --rank_in ../kg_explain/output/bridge_origin_reassess.csv \
    --out output/step6_origin_reassess \
    --target_disease atherosclerosis --topn 83
```

### åŸç–¾ç—…é‡è¯„ä¼° (Direction B)

ä» V3 æ’åºä¸­æå–ç›®æ ‡ç–¾ç—…ç›¸å…³è¯ç‰©ï¼Œè¯„ä¼°"å¤±è´¥è¯ç‰©æ˜¯å¦çœŸçš„å¯¹åŸç–¾ç—…æ— æ•ˆ"ã€‚

```bash
# é€šç”¨è„šæœ¬ â€” æ¢ç–¾ç—…åªæ”¹ --disease å‚æ•°
python scripts/generate_disease_bridge.py \
    --disease atherosclerosis \
    --inject configs/inject_atherosclerosis.yaml \
    --out output/bridge_origin_reassess.csv

# æ¢å…¶ä»–ç–¾ç—…
python scripts/generate_disease_bridge.py \
    --disease "type 2 diabetes" \
    --out output/bridge_origin_reassess.csv
```

æ–‡çŒ®æ³¨å…¥é…ç½® (`configs/inject_<disease>.yaml`):
```yaml
- name: colchicine
  endpoint_type: CV_EVENTS
  note: "COLCOT/LoDoCo2"
- name: canakinumab
  endpoint_type: CV_EVENTS
  note: "CANTOS"
```

---

## æ•°æ®æº

| æ•°æ®æº | æ¨¡å— | ç”¨é€” | API |
|--------|------|------|-----|
| **CT.gov** | `datasources/ctgov.py` | å¤±è´¥ä¸´åºŠè¯•éªŒ | ClinicalTrials.gov API v2 |
| **RxNorm** | `datasources/rxnorm.py` | è¯ç‰©åæ ‡å‡†åŒ– | RxNav REST API |
| **ChEMBL** | `datasources/chembl.py` | è¯ç‰©â†’é¶ç‚¹æ˜ å°„ | ChEMBL API |
| **Reactome** | `datasources/reactome.py` | é¶ç‚¹â†’é€šè·¯å…³ç³» | Reactome ContentService |
| **OpenTargets** | `datasources/opentargets.py` | åŸºå› â†’ç–¾ç—… + è¡¨å‹ | GraphQL API v4 |
| **FDA FAERS** | `datasources/faers.py` | è¯ç‰©ä¸è‰¯äº‹ä»¶ | openFDA API |
| **Signature** ğŸ†• | `datasources/signature.py` | åŸºå› ç­¾åâ†’è¯ç‰©åæŸ¥ | MyGene.info + ChEMBL |

---

## ç‰ˆæœ¬æ¼”è¿›

| ç‰ˆæœ¬ | è·¯å¾„ç±»å‹ | æ–°å¢èƒ½åŠ› |
|------|----------|----------|
| V1 | Drug â†’ Disease | CT.gov conditions ç›´æ¥å…³è” |
| V2 | Drug â†’ Target â†’ Disease | + ChEMBL é¶ç‚¹æœºåˆ¶ |
| V3 | Drug â†’ Target â†’ Pathway â†’ Disease | + Reactome é€šè·¯ (æ ¸å¿ƒ DTPD) |
| V4 | V3 + Evidence Pack | + æ¯å¯¹è¯æ®åŒ… (JSON) |
| **V5** | **å®Œæ•´å¯è§£é‡Šè·¯å¾„** | **+ FAERS å®‰å…¨ä¿¡å· + ç–¾ç—…è¡¨å‹åŠ æˆ** |
| **V5-Sig** ğŸ†• | **V5 + Signature è¯ç‰©æ¥æº** | **+ åŸºå› ç­¾ååæŸ¥ + å·²çŸ¥é€‚åº”ç—‡æ ‡è®°** |

---

## V5 è¯„åˆ†å…¬å¼

```
final_score = mechanism_score
              Ã— exp(-w1 Ã— safety_penalty - w2 Ã— trial_penalty)
              Ã— (1 + w3 Ã— log1p(min(n_phenotype, 10)))

æœºåˆ¶åˆ† (V3 DTPD è·¯å¾„):
  path_score = (1 + support_gene_boost Ã— n_support_genes)
               Ã— pathway_score
               Ã— exp(-hub_penalty Ã— target_degree)

å…¶ä¸­:
  w1 = 0.3 (safety_penalty_weight)
  w2 = 0.2 (trial_failure_penalty, Signature æ¨¡å¼è®¾ä¸º 0)
  w3 = 0.1 (phenotype_overlap_boost)
  support_gene_boost = 0.15
  hub_penalty = 1.0
  æ¯å¯¹è¯-ç–¾ç—…ä¿ç•™ top-10 paths
```

---

## V5 è¯æ®åŒ…æ ¼å¼

æ¯ä¸ª `evidence_pack_v5/{drug}__{disease}.json` åŒ…å«:

```json
{
  "drug": "tofacitinib citrate",
  "disease": {"id": "EFO_0000685", "name": "rheumatoid arthritis"},
  "scores": {
    "final": 10.58,
    "mechanism": 8.54,
    "safety_penalty": 0.0,
    "trial_penalty": 0.0
  },
  "explainable_paths": [
    {
      "type": "DTPD",
      "path_score": 2.15,
      "nodes": [
        {"type": "Drug",    "id": "tofacitinib citrate"},
        {"type": "Target",  "id": "CHEMBL2148"},
        {"type": "Pathway", "id": "R-HSA-449147", "name": "Signaling by Interleukins"},
        {"type": "Disease", "id": "EFO_0000685", "name": "rheumatoid arthritis"}
      ],
      "explanation": "tofacitinib citrate targets CHEMBL2148 (JAK3), which..."
    }
  ],
  "safety_signals": [...],
  "trial_evidence": [],
  "phenotypes": [...]
}
```

---

## Signature æ¨¡å¼åæŸ¥æµç¨‹

```
Gene Symbol (e.g. JAK3, BTK from disease signature)
  â†’ MyGene.info: /v3/query?q=JAK3&species=human&fields=uniprot,ensembl
  â†’ UniProt Accession (e.g. P52333)
  â†’ ChEMBL: /target.json?target_components__accession=P52333
  â†’ target_chembl_id (e.g. CHEMBL2148)
  â†’ ChEMBL: /mechanism.json?target_chembl_id=CHEMBL2148
  â†’ æ‰€æœ‰è¯ç‰©åˆ†å­ + mechanism_of_action
  â†’ ChEMBL: /molecule/{id}.json â†’ max_phase â‰¥ 2 (Phase II+)
  â†’ å€™é€‰è¯ç‰©åˆ—è¡¨

åŒæ—¶:
  â†’ ChEMBL: /drug_indication.json?molecule_chembl_id=X
  â†’ å·²çŸ¥é€‚åº”ç—‡åˆ—è¡¨ â†’ is_known_indication æ ‡è®°
```

---

## é…ç½®å‚è€ƒ

<details>
<summary>å®Œæ•´é…ç½®é¡¹è¯´æ˜ (å±•å¼€)</summary>

### base.yaml â€” åŸºç¡€é…ç½®

```yaml
# API ç«¯ç‚¹
api:
  ctgov: "https://clinicaltrials.gov/api/v2/studies"
  rxnorm: "https://rxnav.nlm.nih.gov/REST/approximateTerm.json"
  chembl: "https://www.ebi.ac.uk/chembl/api/data"
  reactome: "https://reactome.org/ContentService"
  opentargets: "https://api.platform.opentargets.org/api/v4/graphql"
  faers: "https://api.fda.gov/drug/event.json"

# HTTP è®¾ç½®
http:
  timeout: 60
  max_retries: 5
  page_size: 200

# æ’åºå‚æ•°
rank:
  topk_paths_per_pair: 10
  topk_pairs_per_drug: 50
  hub_penalty_lambda: 1.0
  support_gene_boost: 0.15
```

### versions/v5_signature.yaml â€” Signature æ¨¡å¼å‚æ•°

```yaml
mode: v5

signature:
  max_phase: 2          # Phase II+ è¯ç‰©
  max_genes: 100        # å‰100ä¸ªç­¾ååŸºå› 
  gene_source: both     # up + down éƒ½ç”¨

rank:
  safety_penalty_weight: 0.3
  trial_failure_penalty: 0.0    # Signature æ¨¡å¼æ— è¯•éªŒæ•°æ®
  phenotype_overlap_boost: 0.1

faers:
  min_report_count: 5
  min_prr: 1.5
```

### diseases/atherosclerosis.yaml â€” ç–¾ç—…é…ç½®

```yaml
condition: "atherosclerosis"
drug_filter:
  include: [DRUG, BIOLOGICAL]
  exclude: [DEVICE, PROCEDURE, BEHAVIORAL, DIETARY_SUPPLEMENT]
icd10: [I70, I25, I73.9]
mesh_terms:
  - Atherosclerosis
  - Coronary Artery Disease
  - Peripheral Arterial Disease
```

</details>

---

## é¡¹ç›®ç»“æ„

```
kg_explain/
â”œâ”€â”€ src/kg_explain/                  æºä»£ç 
â”‚   â”œâ”€â”€ __init__.py                 ç‰ˆæœ¬ 0.7.0
â”‚   â”œâ”€â”€ __main__.py                 å…¥å£
â”‚   â”œâ”€â”€ cli.py                      å‘½ä»¤è¡Œ (pipeline + fetch + rank + build)
â”‚   â”œâ”€â”€ config.py                   é…ç½®åŠ è½½ + éªŒè¯
â”‚   â”œâ”€â”€ cache.py                    HTTP ç¼“å­˜ (TTL + å¹¶å‘)
â”‚   â”œâ”€â”€ utils.py                    å·¥å…·å‡½æ•° (concurrent_map, CSV I/O)
â”‚   â”œâ”€â”€ graph.py                    NetworkX çŸ¥è¯†å›¾è°±æ„å»º
â”‚   â”œâ”€â”€ datasources/                7 ä¸ªæ•°æ®æºæ¨¡å—
â”‚   â”‚   â”œâ”€â”€ ctgov.py               CT.gov å¤±è´¥è¯•éªŒ
â”‚   â”‚   â”œâ”€â”€ rxnorm.py              RxNorm è¯ç‰©åæ ‡å‡†åŒ–
â”‚   â”‚   â”œâ”€â”€ chembl.py              ChEMBL è¯ç‰©â†’é¶ç‚¹æ˜ å°„
â”‚   â”‚   â”œâ”€â”€ reactome.py            Reactome é€šè·¯ (å¹¶è¡Œ)
â”‚   â”‚   â”œâ”€â”€ opentargets.py         OpenTargets åŸºå› â†’ç–¾ç—…
â”‚   â”‚   â”œâ”€â”€ faers.py               FAERS ä¸è‰¯äº‹ä»¶ (PRR)
â”‚   â”‚   â””â”€â”€ signature.py           ğŸ†• åŸºå› ç­¾åâ†’è¯ç‰©åæŸ¥
â”‚   â”œâ”€â”€ builders/                   è¾¹æ„å»º
â”‚   â”‚   â””â”€â”€ edges.py               gene_pathway, pathway_disease, trial_ae
â”‚   â”œâ”€â”€ rankers/                    æ’åºç®—æ³• V1-V5
â”‚   â”‚   â”œâ”€â”€ v1.py ~ v5.py         å„ç‰ˆæœ¬æ’åºå™¨
â”‚   â”‚   â”œâ”€â”€ base.py                hub_penalty ç­‰å…±äº«å·¥å…·
â”‚   â”‚   â”œâ”€â”€ uncertainty.py         Bootstrap CI ä¸ç¡®å®šæ€§é‡åŒ– (1000x é‡é‡‡æ ·)
â”‚   â”‚   â””â”€â”€ __init__.py            run_pipeline è°ƒåº¦å™¨
â”‚   â”œâ”€â”€ evaluation/                 è¯„ä¼°æ¨¡å—
â”‚   â”‚   â”œâ”€â”€ metrics.py             Hit@K, MRR, P@K, AP, NDCG@K, AUROC
â”‚   â”‚   â”œâ”€â”€ benchmark.py           Gold-standard è¯„ä¼° + æŠ¥å‘Š (å« CI + leakage æ®µ)
â”‚   â”‚   â”œâ”€â”€ external_benchmarks.py Hetionet CtD å¤–éƒ¨éªŒè¯
â”‚   â”‚   â”œâ”€â”€ temporal_split.py      æ—¶é—´åˆ†å‰²éªŒè¯ (é›†æˆ leakage audit)
â”‚   â”‚   â””â”€â”€ leakage_audit.py       æ•°æ®æ³„æ¼å®¡è®¡ (drug/disease/pair é‡å æ£€æµ‹)
â”‚   â””â”€â”€ governance/                 æ²»ç†æ¨¡å—
â”‚       â”œâ”€â”€ quality_gate.py        æŒ‡æ ‡é˜ˆå€¼é—¨æ§ + å›å½’å®¹å¿æ£€æŸ¥
â”‚       â”œâ”€â”€ registry.py            æ¨¡å‹ç‰ˆæœ¬æ³¨å†Œ (config hash + data hash + metrics)
â”‚       â””â”€â”€ regression.py          å›å½’æµ‹è¯•å¥—ä»¶ (å›ºå®š input/output fixtures)
â”‚
â”œâ”€â”€ configs/                        é…ç½®æ–‡ä»¶
â”‚   â”œâ”€â”€ base.yaml                  é€šç”¨è®¾ç½®
â”‚   â”œâ”€â”€ diseases/
â”‚   â”‚   â””â”€â”€ atherosclerosis.yaml   ç–¾ç—…æ–¹å‘
â”‚   â””â”€â”€ versions/
â”‚       â”œâ”€â”€ v5.yaml                V5 å‚æ•° (CT.gov æ¨¡å¼)
â”‚       â””â”€â”€ v5_signature.yaml      ğŸ†• V5 å‚æ•° (Signature æ¨¡å¼)
â”‚
â”œâ”€â”€ data/                           ä¸­é—´æ•°æ® (~20+ ä¸ª CSV)
â”œâ”€â”€ output/                         æœ€ç»ˆè¾“å‡º
â”œâ”€â”€ cache/                          HTTP ç¼“å­˜ (gitignored)
â”œâ”€â”€ tests/                          æµ‹è¯•æ–‡ä»¶
â”œâ”€â”€ requirements.txt               ä¾èµ–
â””â”€â”€ pytest.ini                     æµ‹è¯•é…ç½®
```

---

## è¿è¡Œæ€§èƒ½

### CT.gov æ¨¡å¼ (V5, atherosclerosis)
- æ€»è€—æ—¶: **~4.6 åˆ†é’Ÿ** (278s, ç¼“å­˜çƒ­å¯åŠ¨)
- è¾“å…¥è¯ç‰©: 46 ä¸ª (æ¥è‡ªå¤±è´¥è¯•éªŒ)
- è¾“å‡ºè¯-ç–¾ç—…å¯¹: 54,000+

### Signature æ¨¡å¼ (V5, atherosclerosis) ğŸ†•
- æ€»è€—æ—¶: **~5.8 åˆ†é’Ÿ** (349s, ç¼“å­˜çƒ­å¯åŠ¨)
- è¾“å…¥åŸºå› : 100 ä¸ª (from disease signature)
- å‘ç°è¯ç‰©: 31 ä¸ª (max_phase â‰¥ 4, æ¥è‡ª 8 ä¸ªç­¾ååŸºå› é¶ç‚¹)
- è¯ç‰©ç±»åˆ«: JAK æŠ‘åˆ¶å‰‚ã€BTK æŠ‘åˆ¶å‰‚ã€å¹²æ‰°ç´ ã€å¼ºå¿ƒè‹·ã€æŠ— CD52 ç­‰
- è¾“å‡ºè¯-ç–¾ç—…å¯¹: 1,550
- å·²çŸ¥é€‚åº”ç—‡æ ‡è®°: 200 å¯¹

---

## å¸¸è§é—®é¢˜

**Q: CT.gov æ¨¡å¼å’Œ Signature æ¨¡å¼æœ‰ä»€ä¹ˆåŒºåˆ«?**
A: CT.gov ä»å¤±è´¥è¯•éªŒè·å–è¯ç‰© (åŒç–¾ç—…é¢†åŸŸå†…)ï¼ŒSignature ä»åŸºå› ç­¾ååæŸ¥è¯ç‰© (è·¨ç–¾ç—…é¢†åŸŸ)ã€‚åè€…æ›´é€‚åˆå‘ç°"ç”¨ A ç–¾ç—…çš„è¯æ²» B ç–¾ç—…"çš„ repurposing å€™é€‰ã€‚

**Q: max_phase â‰¥ 2 åŒ…æ‹¬å“ªäº›è¯ç‰©?**
A: Phase II (ä¸´åºŠ II æœŸ)ã€Phase III (ä¸´åºŠ III æœŸ)ã€Phase IV (å·²ä¸Šå¸‚)ã€‚è®¾ä¸º 2 å¯ä»¥åŒ…å«æ›´å¤šå€™é€‰è¯ç‰©ã€‚

**Q: is_known_indication æ˜¯æ€ä¹ˆåˆ¤æ–­çš„?**
A: é€šè¿‡ ChEMBL `drug_indication` API æŸ¥è¯¢æ¯ä¸ªè¯ç‰©çš„æ‰€æœ‰å·²çŸ¥é€‚åº”ç—‡ (EFO/MESH ID)ï¼Œä¸æ’åä¸­çš„ disease ID åšäº¤å‰åŒ¹é…ã€‚åŒ¹é…ä¸Šçš„æ ‡è®°ä¸º Trueã€‚

**Q: ä¸ºä»€ä¹ˆ 100 ä¸ªç­¾ååŸºå› åªæœ‰å°‘æ•°äº§å‡ºè¯ç‰©?**
A: å¤§å¤šæ•°ç–¾ç—…åŸºå› å°šæ— å·²æ‰¹å‡†/åœ¨ç ”è¯ç‰©é¶å‘ã€‚è¿™æ˜¯æ­£å¸¸çš„ â€” "å¯æˆè¯é¶ç‚¹" (druggable targets) åœ¨äººç±»åŸºå› ç»„ä¸­å å°‘æ•°ã€‚

**Q: å¦‚ä½•æ·»åŠ æ–°çš„ç–¾ç—…æ–¹å‘?**
A: åœ¨ `configs/diseases/` ä¸‹åˆ›å»ºæ–° YAMLï¼ŒæŒ‡å®š `condition` (CT.gov æœç´¢è¯)ã€‚Signature æ¨¡å¼è¿˜éœ€è¦è¯¥ç–¾ç—…çš„ `disease_signature_meta.json`ã€‚

**Q: ç»„åˆè¯ (å¦‚ "aspirin+ticagrelor") åˆ†æ•°ä¸ºä»€ä¹ˆåé«˜?**
A: ç»„åˆè¯é¶ç‚¹å¤šäºå•è¯ï¼Œæœºåˆ¶åˆ†è¢«æ”¾å¤§ã€‚V5 å·²æŒ‰ç»„åˆ†æ•°é‡å½’ä¸€åŒ–ã€‚

---

## è´¨é‡ä¿éšœæ¨¡å— (2026-02-12)

| æ¨¡å— | æ–‡ä»¶ | åŠŸèƒ½ |
|------|------|------|
| **Bootstrap CI** | `rankers/uncertainty.py` | 1000x é‡é‡‡æ ·ç½®ä¿¡åŒºé—´, HIGH/MEDIUM/LOW åˆ†å±‚ |
| **Leakage Audit** | `evaluation/leakage_audit.py` | Drug/disease/pair ä¸‰çº§æ³„æ¼æ£€æµ‹ |
| **Temporal Split** | `evaluation/temporal_split.py` | æŒ‰å¹´ä»½åˆ‡å‰² train/test, è‡ªåŠ¨é›†æˆ leakage audit |
| **External Benchmark** | `evaluation/external_benchmarks.py` | Hetionet CtD é‡‘æ ‡å‡†, 6+ æŒ‡æ ‡ |
| **Quality Gate** | `governance/quality_gate.py` | æŒ‡æ ‡é˜ˆå€¼ + å›å½’å®¹å¿ (baseline å¯¹æ¯”) |
| **Model Registry** | `governance/registry.py` | config hash + data hash + metrics å¿«ç…§ |
| **Regression Suite** | `governance/regression.py` | å›ºå®š fixture å›å½’æµ‹è¯• |

V5 æ’åºåè‡ªåŠ¨é™„åŠ  Bootstrap CI åˆ—:
- `ci_lower` / `ci_upper`: 95% ç½®ä¿¡åŒºé—´
- `ci_width`: åŒºé—´å®½åº¦
- `confidence_tier`: HIGH (<0.10) / MEDIUM (<0.25) / LOW (>=0.25)
- `n_evidence_paths`: è¯¥ pair çš„è¯æ®è·¯å¾„æ•°

benchmark æŠ¥å‘Šè‡ªåŠ¨åŒ…å« Uncertainty Summary + Data Leakage Audit æ®µè½ã€‚

**æµ‹è¯•**: 335 tests å…¨é€šè¿‡

---

## å…è´£å£°æ˜
- ç»“æœåŸºäºå…¬å¼€æ•°æ®åº“ (CT.gov, ChEMBL, Reactome, OpenTargets, FAERS) çš„è‡ªåŠ¨åŒ–æ•´åˆï¼Œä¸ç­‰äºä¸´åºŠéªŒè¯ã€‚
- Hub é¶ç‚¹ (å¦‚æ¿€é…¶å®¶æ—) å·²æƒ©ç½šä½†ä»å¯èƒ½å¼•å…¥å™ªå£°ã€‚
- FAERS å®‰å…¨ä¿¡å·ä¸ºå¯å‘å¼ï¼Œéœ€ç»“åˆä¸“ä¸šåˆ¤æ–­ã€‚
- å·²çŸ¥é€‚åº”ç—‡æ ‡è®°åŸºäº ChEMBL æ•°æ®ï¼Œå¯èƒ½ä¸å®Œæ•´ã€‚
